腎バイオメーカーの市場規模、シェア、成長分析、バイオマーカー別、診断技法別、地域別 - 産業予測、2025～2032年

腎バイオメーカーの世界市場規模は、2023年に12億9,000万米ドルと評価され、2024年の13億9,000万米ドルから2032年には24億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.6％で成長する見通しです。

世界の腎臓バイオマーカー市場は、腎臓病に対する精密な診断ツールやオーダーメイドの治療戦略に対する需要の高まりを背景に、力強い成長軌道に乗っています。腎機能の重要な指標となるバイオマーカーは、慢性腎臓病や急性腎障害などの疾患の早期発見やモニタリングに役立ちます。人口の高齢化と糖尿病や高血圧などの生活習慣要因によって腎疾患の有病率が上昇していることが、この需要をさらに押し上げています。バイオマーカー検出の技術的進歩により、検査の精度と信頼性が大幅に向上し、情報に基づいた臨床的意思決定が容易になった。しかし、包括的な評価のために複数のバイオマーカーを必要とする腎疾患の複雑さ、規制上のハードル、標準化された検査プロトコルの必要性などの課題に直面しており、臨床現場での普及の妨げとなっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

腎バイオメーカー市場規模：バイオマーカー別

• 市場概要
• 機能バイオマーカー
  • 血清クレアチニン
  • 血清シスタチンC
  • 尿アルブミン
• アップレギュレートされたタンパク質
  • 好中球ゼラチナーゼ関連リポカリン
  • 腎臓損傷分子-1
  • インターロイキン-18
• その他

腎バイオメーカー市場規模：診断技法別

• 市場概要
• 酵素免疫測定法（ELISA）
• 粒子増強比濁免疫測定法（PETIA）
• 比色分析
• 化学発光酵素免疫測定法（CLIA）
• 液体クロマトグラフィー質量分析法（LS-MS）

腎バイオメーカー市場規模：エンドユーザー別

• 市場概要
• 診断ラボ
• 外来診療所
• 研究センター
• 病院

腎バイオメーカー市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
• 収益の前年比比較（2022-2024）

主要企業プロファイル

• Abbott Laboratories
• BioPorto Diagnostics AS
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• SEKISUI MEDICAL CO., LTD.
• BioMerieux SA
• Sphingotec GmbH
• Randox Laboratories Ltd
• Siemens Healthineers AG
• Enzo Life Sciences, Inc.
• Beckman Coulter, Inc.（Danaher Corporation）
• Fujirebio Inc.
• Bio-Rad Laboratories, Inc.
• Nova Biomedical Corporation
• Sysmex Corporation
• ACON Laboratories, Inc.
• Gold Standard Diagnostics Corp.
• R&D Systems, Inc.（Bio-Techne Corporation）
• Dako（Agilent Technologies, Inc.）
• DiaSorin S.p.A.

結論と推奨事項

Global Renal Biomakers Market size was valued at USD 1.29 billion in 2023 and is poised to grow from USD 1.39 billion in 2024 to USD 2.49 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032).

The global renal biomarkers market is on a robust growth trajectory, driven by an escalating demand for precise diagnostic tools and tailored treatment strategies for kidney diseases. As key indicators of renal function, these biomarkers enhance the early detection and monitoring of conditions such as chronic kidney disease and acute kidney injury. The rising prevalence of renal diseases, exacerbated by aging populations and lifestyle factors like diabetes and hypertension, propels this demand further. Technological advancements in biomarker detection have significantly improved test accuracy and reliability, facilitating informed clinical decision-making. However, the market faces challenges, including the complexities of renal conditions necessitating multiple biomarkers for comprehensive assessments, regulatory hurdles, and the need for standardized testing protocols, which can hinder widespread adoption in clinical settings.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Renal Biomakers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Renal Biomakers Market Segmental Analysis

Global Renal Biomakers Market is segmented on the basis of type, end-user, and region. By type, the market is segmented into functional biomarkers, up-regulated proteins, and other biomarker types. By end user, the market is segmented into hospitals, diagnostic laboratories, and other end users. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Renal Biomakers Market

One of the primary factors propelling the Global Renal Biomarkers market is the rising prevalence of renal diseases, such as chronic kidney disease (CKD), acute kidney injury (AKI), and kidney failure. As the rates of these conditions continue to increase, there is a heightened need for renal biomarkers, which are essential for the early detection, precise diagnosis, and effective monitoring of kidney-related ailments. These biomarkers are instrumental in facilitating timely medical interventions and enhancing patient outcomes, thereby significantly driving market growth and reinforcing their critical importance in healthcare strategies aimed at managing renal health.

Restraints in the Global Renal Biomakers Market

The Global Renal Biomarkers market faces various restraints, particularly due to regulatory challenges. The intricate and continuously changing regulatory environment surrounding biomarkers poses hurdles in acquiring necessary approvals and adhering to stringent quality and safety standards. This process can be lengthy and demand significant resources, ultimately impeding market growth and stifling innovation within the industry. Navigating these complex regulatory pathways presents a significant barrier for companies striving to develop and commercialize renal biomarkers, potentially delaying their entry into the market and affecting overall advancements in renal healthcare solutions.

Market Trends of the Global Renal Biomakers Market

The Global Renal Biomarkers market is witnessing a significant trend towards the increasing adoption of personalized medicine, which is reshaping patient care in nephrology. Healthcare providers are increasingly leveraging renal biomarkers to create individualized treatment strategies that take into account each patient's unique characteristics and the progression of their disease. This personalized approach not only enhances the efficacy of targeted therapies but also helps improve overall patient outcomes, fostering a paradigm shift in renal disease management. As a result, the market is expected to expand rapidly, driven by innovations in biomarker research and the growing emphasis on customized healthcare solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Renal Biomakers Market Size by Biomarker & CAGR (2025-2032)

• Market Overview
• Functional Biomarker
  • Serum Creatinine
  • Serum Cystatin C
  • Urine Albumin
• Up-Regulated Proteins
  • Neutrophil Gelatinase-Associated Lipocalin
  • Kidney Injury Molecule-1
  • Interleukin-18
• Others

Global Renal Biomakers Market Size by Diagnostic Technique & CAGR (2025-2032)

• Market Overview
• Enzyme Linked Immunosorbent Assay (ELISA)
• Particle-Enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography-Mass Spectrometry (LS-MS)

Global Renal Biomakers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Diagnostic Labs
• Outpatient Clinics
• Research Centers
• Hospitals

Global Renal Biomakers Market Size & CAGR (2025-2032)

• North America (Biomarker, Diagnostic Technique, End User)
  • US
  • Canada
• Europe (Biomarker, Diagnostic Technique, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker, Diagnostic Technique, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker, Diagnostic Technique, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker, Diagnostic Technique, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioPorto Diagnostics AS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SEKISUI MEDICAL CO., LTD.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sphingotec GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enzo Life Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter, Inc. (Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nova Biomedical Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACON Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gold Standard Diagnostics Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R&D Systems, Inc. (Bio-Techne Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dako (Agilent Technologies, Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations